A new predictive molecular marker for cetuximab benefit in rectal cancer?
- PMID: 24957075
- DOI: 10.1093/jnci/dju154
A new predictive molecular marker for cetuximab benefit in rectal cancer?
Comment on
-
TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial.J Natl Cancer Inst. 2014 Jun 23;106(7):dju121. doi: 10.1093/jnci/dju121. Print 2014 Jul. J Natl Cancer Inst. 2014. PMID: 24957073
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
